Ascendis Pharma A/S- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Ascendis Pharma A/S 公司

Ascendis Pharma A/S 是一家总部位于丹麦的制药产品生产公司。该公司生产的产品用于治疗生长激素缺乏症、内分泌学、中枢神经系统疾病、传染病和糖尿病。该公司通过其子公司在全球开展业务：Ascendis Pharma GmbH（德国）、Ascendis Pharma, Inc.（美国特拉华州）、Ascendis Pharma Endocrinology, Inc.（美国特拉华州）、Ascendis Pharma, Ophthalmology Division A/S（丹麦）、Ascendis Pharma, Endocrinology Division A/S（丹麦）、Ascendis Pharma Bone Diseases A/S（丹麦）、Ascendis Pharma Growth Disorders A/S（丹麦）和 Ascendis Pharma Oncology Division A/S（丹麦）。

公司简介

公司代码ASND

公司名称Ascendis Pharma A/S

上市日期Jan 28, 2015

CEOMr. Jan Moller Mikkelsen

员工数量- -

证券类型Depository Receipt

年结日Jan 28

公司地址Tuborg Boulevard 12

城市HELLERUP

上市交易所NASDAQ Global Select Consolidated

国家Denmark

邮编2900

电话4570222244

网址https://ascendispharma.dk/

公司代码ASND

上市日期Jan 28, 2015

CEOMr. Jan Moller Mikkelsen

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Michael Wolff Jensen

Executive Vice President, Chief Legal Officer, Member of the Executive Board

5.76K

+198.45%

Mr. Flemming Steen Jensen

Executive Vice President, Product Supply and Quality

1.86K

+100.43%

Mr. Lars Holtug, CPA

Independent Director

1.59K

+78.59%

Ms. Lisa Bright

Independent Director

1.09K

+178.01%

Dr. Albert Cha, M.D., Ph.D.

Independent Chairman of the Board

1.09K

+178.01%

Ms. Siham Imani

Independent Director

364.00

--

Mr. Mads Bodenhoff

Senior Vice President, Head of Finance and Principal Accounting Officer

193.00

--

Mr. Donovan (Jay) Wu

Executive Vice President, U.S. President

--

Dr. Aimee Shu,, M.D.

Executive Vice President, Chief Medical Officer

--

Mr. William Carl (Bill) Fairey, Jr.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Michael Wolff Jensen

Executive Vice President, Chief Legal Officer, Member of the Executive Board

5.76K

+198.45%

Mr. Flemming Steen Jensen

Executive Vice President, Product Supply and Quality

1.86K

+100.43%

Mr. Lars Holtug, CPA

Independent Director

1.59K

+78.59%

Ms. Lisa Bright

Independent Director

1.09K

+178.01%

Dr. Albert Cha, M.D., Ph.D.

Independent Chairman of the Board

1.09K

+178.01%

Ms. Siham Imani

Independent Director

364.00

--

收入明细

单位: EUR更新时间: 7月6日周日

FY2025Q1

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务EUR

名称

营收

占比

Commercial sale of products

96.03M

95.12%

Rendering of services

3.52M

3.49%

License

1.40M

1.39%

地区EUR

名称

营收

占比

North America

73.69M

72.99%

Europe

21.33M

21.13%

Rest of world

5.94M

5.88%

业务

地区

业务EUR

名称

营收

占比

Commercial sale of products

96.03M

95.12%

Rendering of services

3.52M

3.49%

License

1.40M

1.39%

股东统计

更新时间: 9月5日周五

持股股东

股东类型

持股股东

占比

RA Capital Management, LP

17.03%

Westfield Capital Management Company, L.P.

9.03%

Avoro Capital Advisors LLC

8.25%

Janus Henderson Investors

7.33%

Fidelity Management & Research Company LLC

6.92%

其他

51.44%

持股股东

占比

RA Capital Management, LP

17.03%

Westfield Capital Management Company, L.P.

9.03%

Avoro Capital Advisors LLC

8.25%

Janus Henderson Investors

7.33%

Fidelity Management & Research Company LLC

6.92%

其他

51.44%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

42.38%

Investment Advisor

37.12%

Venture Capital

17.36%

Hedge Fund

6.18%

Private Equity

1.87%

Research Firm

1.74%

Individual Investor

0.78%

Family Office

0.44%

Family Office

0.44%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

502

70.53M

116.83%

-1.34M

2025Q1

513

68.89M

114.10%

-3.55M

2024Q4

488

67.37M

111.00%

-7.76M

2024Q3

475

65.25M

107.66%

-6.23M

2024Q2

459

63.44M

108.94%

-9.21M

2024Q1

453

63.54M

109.13%

-8.68M

2023Q4

430

62.90M

109.00%

-9.55M

2023Q3

414

62.85M

109.61%

-11.90M

2023Q2

426

63.03M

109.93%

-13.27M

2023Q1

427

63.10M

110.08%

-9.14M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

RA Capital Management, LP

10.28M

17.03%

+168.75K

+1.67%

Mar 31, 2025

Westfield Capital Management Company, L.P.

5.48M

9.08%

-48.98K

-0.89%

Mar 31, 2025

Avoro Capital Advisors LLC

5.22M

8.64%

+114.94K

+2.25%

Mar 31, 2025

Janus Henderson Investors

4.49M

7.43%

+106.57K

+2.43%

Mar 31, 2025

Fidelity Management & Research Company LLC

4.30M

7.13%

-52.57K

-1.21%

Mar 31, 2025

Artisan Partners Limited Partnership

4.26M

7.05%

-193.79K

-4.35%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

3.05M

5.06%

+328.28K

+12.04%

Mar 31, 2025

Capital International Investors

2.87M

4.76%

+11.54K

+0.40%

Mar 31, 2025

MFS Investment Management

1.87M

3.1%

+9.63K

+0.52%

Mar 31, 2025

T. Rowe Price Associates, Inc.

2.26M

3.74%

-27.11K

-1.19%

Mar 31, 2025

持股ETF

更新时间: 8月6日周三

机构名称

占比

Harbor Health Care ETF

18.96%

American Century Focused Dynamic Growth ETF

2.5%

AdvisorShares Dorsey Wright ADR ETF

2.31%

BNY Mellon Innovators ETF

2.21%

Virtus LifeSci Biotech Products ETF

1.96%

Tema Heart & Health ETF

1.3%

ProShares Ultra Nasdaq Biotechnology

1.17%

Main Thematic Innovation ETF

1.05%

Invesco Nasdaq Biotechnology ETF

1.03%

Putnam Sustainable Future ETF

0.9%

Harbor Health Care ETF

占比18.96%

American Century Focused Dynamic Growth ETF

占比2.5%

AdvisorShares Dorsey Wright ADR ETF

占比2.31%

BNY Mellon Innovators ETF

占比2.21%

Virtus LifeSci Biotech Products ETF

占比1.96%

Tema Heart & Health ETF

占比1.3%

ProShares Ultra Nasdaq Biotechnology

占比1.17%

Main Thematic Innovation ETF

占比1.05%

Invesco Nasdaq Biotechnology ETF

占比1.03%

Putnam Sustainable Future ETF

占比0.9%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Ascendis Pharma A/S

194.620USD

Ascendis Pharma A/S

194.620

概览

公司

财务

分析